Collegium Pharmaceutical (NASDAQ:COLL) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a report released on Monday morning,Benzinga reports. HC Wainwright currently has a $50.00 price objective on the specialty pharmaceutical company’s stock.

Several other analysts have also commented on COLL. Piper Sandler cut their target price on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research report on Friday, January 10th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $43.60.

Collegium Pharmaceutical Stock Performance

COLL opened at $30.56 on Monday. The business has a 50 day moving average price of $30.63 and a two-hundred day moving average price of $32.59. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The company has a market capitalization of $962.21 million, a price-to-earnings ratio of 13.17 and a beta of 0.99. Collegium Pharmaceutical has a 1-year low of $27.28 and a 1-year high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The business had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. Research analysts predict that Collegium Pharmaceutical will post 5.62 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Shirley R. Kuhlmann sold 40,000 shares of the company’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the transaction, the executive vice president now owns 154,204 shares in the company, valued at $4,330,048.32. This represents a 20.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Colleen Tupper sold 10,445 shares of the firm’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total transaction of $313,454.45. Following the sale, the chief financial officer now owns 165,246 shares of the company’s stock, valued at approximately $4,959,032.46. This represents a 5.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 109,193 shares of company stock valued at $3,243,594. Company insiders own 3.98% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. New Age Alpha Advisors LLC acquired a new position in Collegium Pharmaceutical in the fourth quarter worth approximately $40,000. TD Private Client Wealth LLC increased its position in Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after buying an additional 483 shares during the last quarter. KBC Group NV increased its position in Collegium Pharmaceutical by 72.5% during the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after buying an additional 982 shares during the last quarter. Virtus Fund Advisers LLC raised its holdings in Collegium Pharmaceutical by 30.5% during the fourth quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock valued at $69,000 after buying an additional 565 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in shares of Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after buying an additional 316 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.